Results 241 to 250 of about 6,089,774 (311)

Pre-clinical impact of higher irrigation flow rates during pulsed field ablation with a variable loop circular catheter. [PDF]

Europace
Zou F, Zhang XD, Gomez T, Byun E, Chen Q, Marazzato J, Schiavone M, Mohanty S, La Fazia VM, Motta J, Rosales CZ, Pandey S, Safren L, Shafir Y, Grupposo V, Ynoa D, Lin A, Lakkireddy D, Natale A, Guttenplan N, Di Biase L.   +20 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration. [PDF]

Acta Neuropathol
Richardson TE, Cherry J, Kandoi S, Rohde SK, Uretsky M, Tuz-Zahra F, Bieniek KF, Farrell K, Hefti MM, Miller MB, Tripodis Y, Stein TD, Maldonado-Díaz C, Hiya S, Beach TG, Corrada MM, Dugger BN, Flanagan ME, Frosch MP, Gearing M, Grinberg LT, Hansen LA, Hawes D, Head E, Keene CD, Kofler J, Lee EB, Nelson PT, Oakley DH, Perrin RJ, Rissman RA, Salamat S, Schneider JA, Serrano GE, Teich AF, Troncoso JC, Wisniewski T, Woltjer RL, Crary JF, Dickson DW, McKee AC, Walker JM.   +41 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Promise to Practice: Reimagining Artificial Intelligence for Equitable Global Health Impact. [PDF]

Ann Glob Health
Patel S, Robsky KO, Mao W, Usman U, Garcia L, Omobowale O, Mchunu G, Sung J, Clifford G, Madabhushi A, Ismail A, Bidiwala S, Mehmood S, Ngaruiya C, Kilgore PE, Martin K.   +15 more
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Correction: Next‑Generation SCS Programming Platform: Enhancing ECAP Fidelity and Objectivity to Improve Patient Experience. [PDF]

Pain Ther
Parker DJ, Antony AB, Smith GL, Goree JH, Russo MA, Petersen EA, Vu CM, Verrills P, Gilmore C, Kapural L, Nanavati D, Karantonis DM, Pope JE.   +12 more
europepmc   +1 more source

Truman Doctrine and Marshall Plan in Turkey-USA Relations

Barış ERTEM
openalex   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis. [PDF]

Cardiooncology
Mitchell JD, Pfeiffer M, Boehmer J, Gorcsan J, Eguchi S, Orihara Y, Dronamraju N, Dhani S, Faderl S, Lin TL, Uy GL, Lancet JE, Cortes JE.   +12 more
europepmc   +1 more source